Historically, biotechnology stocks trade at premiums relative to the healthcare and the broader market. That’s simply the price of admission investors to pay to access the attractive growth prospects of biotech. Following a surprisingly lengthy slump by biotech stocks — one including 2023 lethargy — some of the group are sporting attractive valuations. Investors that [...] The post Bevy of Biotech Bargains in BBH appeared first on ETF Trends .